JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

ABT

134.76

+1.17%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

ABT

134.76

+1.17%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

ABT

134.76

+1.17%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

ABT

134.76

+1.17%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

ABT

134.76

+1.17%↑

Search

Eli Lilly and Co.

Slēgts

SektorsVeselības aprūpe

757.36 3.2

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

732.88

Max

758.64

Galvenie mērījumi

By Trading Economics

Ienākumi

-6.1B

2.8B

Pārdošana

-804M

13B

P/E

Sektora vidējais

61.579

56.602

EPS

3.34

Dividenžu ienesīgums

0.82

Peļņas marža

21.678

Darbinieki

47,000

EBITDA

-2B

4.2B

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+37.39% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

0.82%

2.45%

Nākamie ieņēmumi

2025. g. 6. aug.

Nākamais dividenžu datums

2025. g. 10. jūn.

Nākamais Ex dividenžu datums

2025. g. 16. maijs

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-149B

678B

Iepriekšējā atvēršanas cena

754.16

Iepriekšējā slēgšanas cena

757.36

Ziņu noskaņojums

By Acuity

63%

37%

335 / 382 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

Eli Lilly and Co. Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 1. maijs 11:24 UTC

Peļņas

Eli Lilly 1Q Revenue Surges on Demand for Mounjaro, Other Weight-Loss Treatments

2025. g. 22. apr. 09:26 UTC

Galvenie tirgus virzītāji

Novo Nordisk Shares Fall After Data From New Eli Lilly Pill

2025. g. 18. apr. 15:57 UTC

Galvenie tirgus virzītāji

Eli Lilly CEO Ricks Warns Against Unintentionally Raising Prices as Weight-Loss Pill Nears Market Launch

2025. g. 12. maijs 22:14 UTC

Top Ziņas

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

2025. g. 12. maijs 18:45 UTC

Top Ziņas

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

2025. g. 12. maijs 17:14 UTC

Top Ziņas

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- WSJ

2025. g. 7. maijs 17:01 UTC

Top Ziņas

Teva Will Hike Generic Drug Prices If Trump Imposes Tariffs, CEO Says -- Barrons.com

2025. g. 7. maijs 13:56 UTC

Peļņas

Novo Nordisk Stock Jumps After Earnings. Compounding Market's Growth Took it By Surprise -- Barrons.com

2025. g. 7. maijs 11:18 UTC

Peļņas

Novo Nordisk Stock Jumps After Earnings. It Cuts Guidance as Weight-Loss Drug Sales Slow. -- Barrons.com

2025. g. 7. maijs 09:30 UTC

Top Ziņas

Trump Is Threatening Big Pharma With Tariffs. Tax Changes Might Work Better. -- Heard on the Street -- WSJ

2025. g. 6. maijs 20:30 UTC

Top Ziņas

Novo Nordisk Reports Earnings Soon. The Wegovy Manufacturer Is Scrambling to Hold Market Share. -- Barrons.com

2025. g. 4. maijs 04:05 UTC

Iegādes, apvienošanās, pārņemšana

UnitedHealth's Stock Is Ailing. A Bigger Business Hasn't Helped. -- Barrons.com

2025. g. 1. maijs 21:07 UTC

Tirgus saruna

Weight-Loss Drug Competitive Pressures Hammer Eli Lilly Shares -- Market Talk

2025. g. 1. maijs 14:07 UTC

Peļņas

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

2025. g. 1. maijs 12:47 UTC

Peļņas

These Stocks Are Moving the Most Today: Microsoft, Meta, Tesla, Apple, CVS, Eli Lilly, McDonald's, Moderna, and More -- Barrons.com

2025. g. 1. maijs 12:00 UTC

Top Ziņas

Lower Taxes Could Bring More Drug Production to U.S., Says Eli Lilly CEO -- WSJ

2025. g. 1. maijs 11:58 UTC

Peļņas

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

2025. g. 1. maijs 11:06 UTC

Peļņas

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

2025. g. 1. maijs 10:48 UTC

Peļņas

Eli Lilly Earnings Beat Expectations. The Stock Is Falling. -- Barrons.com

2025. g. 1. maijs 10:48 UTC

Peļņas

Eli Lilly Sees FY Rev $58.0B-$61.0B >LLY

2025. g. 1. maijs 10:45 UTC

Peļņas

Eli Lilly 1Q Adj EPS $3.34 >LLY

2025. g. 1. maijs 10:45 UTC

Peļņas

Eli Lilly Sees FY EPS $20.17-EPS $21.67 >LLY

2025. g. 1. maijs 10:45 UTC

Peļņas

Eli Lilly 1Q Net $2.76B >LLY

2025. g. 1. maijs 10:45 UTC

Peļņas

Eli Lilly 1Q Rev $12.73B >LLY

2025. g. 1. maijs 10:45 UTC

Peļņas

Eli Lilly 1Q EPS $3.06 >LLY

2025. g. 1. maijs 10:45 UTC

Peļņas

Eli Lilly Sees FY Adj EPS $20.78-Adj EPS $22.28 >LLY

2025. g. 30. apr. 09:30 UTC

Top Ziņas

Why New Wegovy Deals Won't Restore Novo's Obesity Lead -- Heard on the Street -- WSJ

2025. g. 28. apr. 13:58 UTC

Top Ziņas

IBM, Apple, Eli Lilly: Tracking Corporate Spending Pledges Under Trump -- WSJ

2025. g. 22. apr. 09:31 UTC

Karstas akcijas

Stocks to Watch Tuesday: Tesla, Novo Nordisk, Hertz -- WSJ

2025. g. 17. apr. 18:27 UTC

Top Ziņas

Lilly's First Pill for Diabetes, Weight Loss Shows Positive Study Results -- Update

Salīdzinājums

Cenas izmaiņa

Eli Lilly and Co. Prognoze

Cenas mērķis

By TipRanks

37.39% augšup

Prognoze 12 mēnešiem

Vidējais 983.13 USD  37.39%

Augstākais 1,124 USD

Zemākais 700 USD

Pamatojoties uz 20 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Eli Lilly and Co. — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

20 ratings

18

Pirkt

1

Turēt

1

Pārdot

Tehniskais rādītājs

By Trading Central

N/A / 884.54Atbalsts un pretestība

Īstermiņā

Very Strong Bearish Evidence

Vidējā termiņā

Bullish Evidence

Ilgtermiņā

Strong Bearish Evidence

Noskaņojums

By Acuity

335 / 382 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Lāču" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.